Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 58

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Study on Inhaled Seralutinib (GB002) for Patients with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Exudative retinopathy

Not recruiting

Study on Bevacizumab Injections for Patients with Coats' Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Bevacizumab
  • Sponsor:Fondation A De Rothschild
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Thoraxklinik Heidelberg gGmbH

Study on Bempedoic Acid with Atorvastatin and Ezetimibe for Patients with Coronary Artery Disease After Heart Attack

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Medizinische Hochschule Hannover

Ischaemic stroke

Not recruiting

Study on Blood Pressure Management with Urapidil, Phenylephrine, and Labetalol for Patients with Acute Ischemic Stroke After Endovascular Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Urapidil
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Study on the Effect of Aflibercept Injections in Patients with Central Retinal Vein Occlusion (CRVO) and Spontaneous Retinal Arterial Pulsations (SRAPs)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Fondation A De Rothschild

Pulmonary hypertension+1

Not recruiting

Study on the Safety and Effectiveness of Apixaban, Edoxaban, and Phenprocoumon for Patients with Chronic Thromboembolic Pulmonary Hypertension Undergoing Balloon Pulmonary Angioplasty

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:St Antonius Hospital

Arteriosclerosis

Not recruiting

Study on the Effect of Evolocumab on Heart Disease in Patients Needing Coronary Angiography

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Oxygen Therapy for Patients with Diabetic Foot Ulcers

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Amsterdam UMC Stichting

Atrial fibrillation+2

Not recruiting

Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Ottawa Heart Institute

Giant cell arteritis

Not recruiting

Study on Tocilizumab and Steroids for Patients with Giant Cell Arteritis and Cerebrovascular Involvement

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on the Effects of Ziltivekimab for Reducing Inflammation in Patients with Coronary Artery Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Amsterdam UMC Stichting

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.